Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Loss of Neupogen sales to U.S. biosimilars 2015-2017

This statistic depicts the value of filgrastim sales from Neupogen compared to its U.S. biosimilar competitors from 2015 to 2017. In 2015, Neupogen generated 810.05 million dollars in sales in the United States. As of November 2017, Neupogen sales decreased to 400.2 million U.S. dollars.

Sales of Neupogen compared to its U.S. biosimilars from 2015 to 2017

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until November 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

February 2018

Region

United States

Survey time period

2015 to 2017

Supplementary notes

* Year to date November 2017.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.